ImmunityBio, Inc. (IBRX)

NASDAQ: IBRX · Real-Time Price · USD

2.620

-0.050 (-1.87%)

Dec 20, 2024, 4:00 PM EST - Market closed

ImmunityBio Employees

ImmunityBio had 628 employees as of December 31, 2023. The number of employees decreased by 97 or -13.38% compared to the previous year.

Employees

628

Change (1Y)

-97

Growth (1Y)

-13.38%

Revenue / Employee

$11,675

Profits / Employee

-$935,978

Market Cap

1.83B

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	628	-97	-13.38%
Dec 31, 2022	725	138	23.51%
Dec 31, 2021	587	322	121.51%
Dec 31, 2019	265	-	-

Related Stocks

Company Name	Employees
Fortrea Holdings	18,000
UFP Technologies	3,093
Amphastar Pharmaceuticals	1,761
Galapagos NV	1,123
Recursion Pharmaceuticals	500
MannKind	414
Arcutis Biotherapeutics	296
Neumora Therapeutics	124

Employee Rankings

IBRX News

6 days ago - ImmunityBio: Forging A New Plan After Recent $100 Million Offering - Seeking Alpha
8 days ago - ImmunityBio: Despite Share Price & Funding Woes, Muddy Path To Long-Term Success - Seeking Alpha
9 days ago - D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering - GlobeNewsWire
10 days ago - ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock - Business Wire
11 days ago - ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock - Business Wire
4 weeks ago - ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment - PRNewsWire
4 weeks ago - ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements - PRNewsWire
4 weeks ago - ImmunityBio Completes ANKTIVA's Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months - Business Wire